Assessing the risk of multiple sclerosis disease-modifying therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessing the risk of multiple sclerosis disease-modifying therapies

Published:2019-06-26 Issue:7 Volume:19 Page:695-706
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Ayrignac Xavier¹,Bilodeau Philippe-Antoine²,Prat Alexandre³,Girard Marc³,Labauge Pierre¹,Le Lorier Jacques⁴,Larochelle Catherine³,Duquette Pierre³

Affiliation:

1. Neurology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France

2. Faculty of Medicine, Neurology, McGill University, Montreal, Canada

3. Neurology, Centre Hospitalier de l’Université de Montréal (CHUM),Montreal, Quebec, Canada

4. Pharmacology, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, Canada

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2019.1627201

Reference111 articles.

1. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

2. Preapproval and postapproval evidence on drugs for multiple sclerosis

3. Safety concerns and risk management of multiple sclerosis therapies

4. Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab

5. Disease-modifying therapies and infectious risks in multiple sclerosis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA—A Preliminary Study;International Journal of Molecular Sciences;2023-05-22

2. CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice;International Journal of Pharmaceutics;2023-04

3. Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol;Systematic Reviews;2022-07-01

4. Pleiotrophin Serum Level is Increased in Relapsing-Remitting Multiple Sclerosis and Correlates With Sex, BMI and Treatment;Archives of Medical Research;2022-01

5. Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society;Revue Neurologique;2021-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3